Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Ankylosing Spondylitis: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
2008-004229-40Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Apremilast with Placebo (2 arms). Primary endpoints: Change in MRI lesions of spine and sacroiliac joints and Change in clinical signs and symptoms of ankylosing spondylitis. Started Nov 2010; status: completed.
02
Drugs
apremilast
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2008-004229-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004229-40.